STX 107

Drug Profile

STX 107

Alternative Names: STX-107

Latest Information Update: 14 Feb 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Developer Seaside Therapeutics
  • Class
  • Mechanism of Action Metabotropic glutamate receptor 5 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Fragile X syndrome

Most Recent Events

  • 19 Dec 2012 Suspended - Phase-II for Fragile X syndrome in USA (PO)
  • 31 May 2011 Phase-II clinical trials in Fragile X syndrome in USA (PO)
  • 03 Nov 2009 Phase-I clinical trials in Fragile X syndrome in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top